Aernoud Fiolet

264 Chapter 10 REFERENCES 1. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, et al.. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019; 381:2497–2505. 2. Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018; 269:262– 271. doi: 10.1016/j.atherosclerosis.2017.12.027 3. Leung YY, Yao Hui LL, Kraus VB. Colchicine: update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45:341–350. 4. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res. 2012; 110:875–888. 5. Fiolet ATL, Nidorf SM, Mosterd A, Cornel JH. Colchicine in stable coronary artery disease.Clin Ther. 2019; 41:30–40.